- Home
- TRMD vs BLTE Comparison
TRMD vs BLTE Comparison
Compare TRMD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- BLTE
- Stock Information
- Founded
- TRMD 1889
- BLTE 2018
- Country
- TRMD United Kingdom
- BLTE United States
- Employees
- TRMD N/A
- BLTE N/A
- Industry
- TRMD Marine Transportation
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- BLTE Health Care
- Exchange
- TRMD Nasdaq
- BLTE Nasdaq
- Market Cap
- TRMD 2.1B
- BLTE 2.1B
- IPO Year
- TRMD N/A
- BLTE 2022
- Fundamental
- Price
- TRMD $20.36
- BLTE $77.01
- Analyst Decision
- TRMD Buy
- BLTE Strong Buy
- Analyst Count
- TRMD 1
- BLTE 4
- Target Price
- TRMD $23.00
- BLTE $96.00
- AVG Volume (30 Days)
- TRMD 649.5K
- BLTE 64.5K
- Earning Date
- TRMD 11-06-2025
- BLTE 11-11-2025
- Dividend Yield
- TRMD 12.76%
- BLTE N/A
- EPS Growth
- TRMD N/A
- BLTE N/A
- EPS
- TRMD 3.31
- BLTE N/A
- Revenue
- TRMD $1,321,800,000.00
- BLTE N/A
- Revenue This Year
- TRMD N/A
- BLTE N/A
- Revenue Next Year
- TRMD N/A
- BLTE N/A
- P/E Ratio
- TRMD $6.16
- BLTE N/A
- Revenue Growth
- TRMD N/A
- BLTE N/A
- 52 Week Low
- TRMD $13.60
- BLTE $49.00
- 52 Week High
- TRMD $33.15
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- TRMD 40.33
- BLTE 70.06
- Support Level
- TRMD $20.41
- BLTE $70.80
- Resistance Level
- TRMD $21.98
- BLTE $74.18
- Average True Range (ATR)
- TRMD 0.46
- BLTE 2.30
- MACD
- TRMD -0.22
- BLTE 0.71
- Stochastic Oscillator
- TRMD 2.90
- BLTE 83.82
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.